Tag: pancreatic cancer
ATG-022, a Claudin 18.2 ADC, Receives Orphan Drug Designations for the...
Shanghai-based biopharmaceutical company Antengene, confirmed that ATG-022, a Claudin 18.2 (CLDN18.2) antibody drug conjugate (ADC) being developed by the company, has been granted two Orphan Drug Designations (ODD) consecutively by the U.S. Food and Drug Administration (FDA) for the treatment of gastric cancer and pancreatic cancer.
ZB131 ADC Induce Potent Anti-tumor Activity CSP-expressing Tumors
Cancer-specific plectin (CSP), a pro-tumorigenic protein selectively expressed on the cell surface of major cancers, is a potentially promising target for the development of novel antibody-drug conjugates (ADC).
U.S. FDA Grants Orphan Drug Designation for OBI-999 in Gastric Cancer
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to OBI Pharma's OBI-999 for the treatment of Gastric Cancer.
Gastric or stomach...
U.S. Food and Drug Administration Accepts Investigational New Drug Application for...
The U.S. Food and Drug Administration (FDA) has accepted the AbGenomics International's Investigational New Drug Application or IND for AbGn-107, the company's antibody-drug conjugate or ADC candidate...
Compugen’s Antibody Drug Conjugate Program Results Presented
This week, during the World ADC Summit being held October 19 - 22, 2015 in San Diego, CA, Compugen presented the status of its predictive...
Fab’-installed Polymeric Micelles Significantly Improve Efficient Drug Delivery to Solid Tumors
To enhance the efficacy of unconjugated antibodies, researchers have optimized their antitumor activity by conjugating them with radionuclides, toxins, or cytotoxic drugs. The choice...
